BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• 

  Deals

  Novartis Boosts Cancer Business with $2.9B MorphoSys Buy

  The Swiss pharma’s dealmaking momentum continues in early 2024 with the acquisition of German biotech MorphoSys in an effort to strengthen its oncology portfolio.

  February 6, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Vertex’s Cystic Fibrosis Triple Combo Aces Pivotal Phase III Program

  The company’s three-drug combination met all primary and key secondary endpoints in two randomized controlled trials in cystic fibrosis patients, paving the way for an application to regulators.

  February 6, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Lilly Beats Q4 Revenue Estimate Fueled by Strong Zepbound, Mounjaro Sales

  Eli Lilly on Tuesday reported more than $9.3 billion in revenue in the fourth quarter of 2023, beating Wall Street expectations, thanks to demand for its weight-loss drug Zepbound and diabetes treatment Mounjaro.

  February 6, 2024

   · 

  3 min read

   · 

  Tyler Patchen
• 

  Policy

  Valneva Sells Chikungunya Vaccine Priority Review Voucher for $103M

  The French vaccine maker on Monday said it sold a priority review voucher, which was awarded by the FDA in November 2023 alongside an approval for its chikungunya vaccine, to an undisclosed buyer.

  February 6, 2024

   · 

  1 min read

   · 

  Tyler Patchen
• 

  Policy

  Drug Shortages Aren’t Over. And There’s Little Progress Toward Ending Them

  With manufacturing issues persisting, last year’s shortages of medicines, including chemotherapies, weight-loss drugs and antibiotics, will continue into 2024.

  February 6, 2024

   · 

  6 min read

   · 

  Tyler Patchen
• 

  Drug Development

  J&J Touts Positive Phase III Results for Antibody in Autoimmune Disorders

  The monoclonal antibody Nipocalimab, which J&J acquired from Momenta Therapeutics, met its primary endpoints in mid-stage and late-stage trials in myasthenia gravis and Sjögren’s disease.

  February 6, 2024

   · 

  1 min read

   · 

  Tyler Patchen
• 

  Drug Development

  GSK’s Blenrep Combo Scores Phase III Win in Multiple Myeloma

  The antibody-drug conjugate, in combination with Takeda’s Velcade and the steroid dexamethasone, reduced the risk of death and disease progression by 59% versus a similar Darzalex-based regimen.

  February 6, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  Opinion: Think Beyond the Utility Patent to Protect Your Portfolio

  Design patents, trademarks, copyright and trade secrets offer lower cost, and sometimes underappreciated, forms of intellectual property.

  February 6, 2024

   · 

  6 min read

   · 

  April Wurster, Jaime Choi, Christopher Franich and David Nigro
• 

  Policy

  The IRA: A Catalyst for Societal Change

  Politics aside, both the government and the pharmaceutical industry want to bring affordable effective therapies to patients. Implementation is the obstacle. Working together is the only way to modify the IRA to do what it intends to do: benefit patients.

  February 6, 2024

   · 

  7 min read

   · 

  Lori Ellis
• Pharm Country

  Aro Biotherapeutics to Present Updates on ABX1100, a CD71 Centyrin – Gys1 siRNA Conjugate for the Treatment of Pompe Disease at the 20th Annual WORLD Symposium 2024 Meeting

  Aro Biotherapeutics to Present Updates on ABX1100, a CD71 Centyrin – Gys1 siRNA Conjugate for the Treatment of Pompe Disease at the 20th Annual WORLD Symposium 2024 Meeting.

  February 6, 2024

   · 

  3 min read